Business Description
Rein Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US00887A2042
Total Employee Number:
10Description
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.9 | |||||
Equity-to-Asset | -1.27 | |||||
Debt-to-Equity | -0.15 | |||||
Debt-to-EBITDA | -0.23 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 47.8 | |||||
3-Year EPS without NRI Growth Rate | 48 | |||||
3-Year FCF Growth Rate | 48.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 28.28 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 45.07 | |||||
9-Day RSI | 45.67 | |||||
14-Day RSI | 45.46 | |||||
3-1 Month Momentum % | -47.05 | |||||
6-1 Month Momentum % | -18.75 | |||||
12-1 Month Momentum % | -32.68 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.4 | |||||
Quick Ratio | 0.4 | |||||
Cash Ratio | 0.33 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -82.4 | |||||
Shareholder Yield % | -3.74 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROA % | -114.49 | |||||
ROIC % | -55.25 | |||||
3-Year ROIIC % | 30.77 | |||||
ROC (Joel Greenblatt) % | -2155200 | |||||
ROCE % | -59.86 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-EBIT | -3.69 | |||||
EV-to-EBITDA | -3.69 | |||||
EV-to-FCF | -4.79 | |||||
Earnings Yield (Greenblatt) % | -27.1 | |||||
FCF Yield % | -20.99 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:RNTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Rein Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.9 | ||
| Beta | 1.7931 | ||
| 3-Year Sharpe Ratio | 0.14 | ||
| 3-Year Sortino Ratio | 0.26 | ||
| Volatility % | 64.91 | ||
| 14-Day RSI | 45.46 | ||
| 14-Day ATR ($) | 0.079257 | ||
| 20-Day SMA ($) | 0.966075 | ||
| 12-1 Month Momentum % | -32.68 | ||
| 52-Week Range ($) | 0.8641 - 2.18 | ||
| Shares Outstanding (Mil) | 85.54 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Rein Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Rein Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 120 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 29 days | ||
| General meeting for 2026 | 2026-07-20 09:00 | In 5 days | ||
| First quarter earnings results for 2026 | 2026-05-15 | 1.13 (-2.59%) | ||
| Annual report for 2025 | 2026-03-26 | 1.30 (+3.17%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 1.35 (-8.16%) | ||
| Second quarter earnings results for 2025 | 2025-08-14 | 1.20 (-0.83%) | ||
| General meeting for 2025 | 2025-06-24 09:00 | 1.50 (-9.09%) | ||
| First quarter earnings results for 2025 | 2025-05-15 | 2.25 (+15.38%) | ||
| Guidance call for 2025 | 2025-05-08 12:00 | 1.63 (+0.70%) |
Show
Entries
Rein Therapeutics Inc Frequently Asked Questions
What is Rein Therapeutics Inc(RNTX)'s stock price today?
The current price of RNTX is $0.93. The 52 week high of RNTX is $2.18 and 52 week low is $0.86.
When is next earnings date of Rein Therapeutics Inc(RNTX)?
The next earnings date of Rein Therapeutics Inc(RNTX) is 2026-08-14 Est..
Does Rein Therapeutics Inc(RNTX) pay dividends? If so, how much?
Rein Therapeutics Inc(RNTX) does not pay dividend.
Guru Commentaries on NAS:RNTX
No articles.
Press Release
Articles on Rein Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers